Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Glasses help surgeons to see cancer cells
Hospital patient
The new high-tech glasses have been used during surgery for the first time.
New technology could eliminate the need for follow-up surgery

Surgeons may be able to visualise cancer cells more easily during surgery, thanks to high-tech glasses developed by Washington University scientists.

The wearable glasses were used during surgery for the first time on February 10 at the Alvin J Siteman Cancer Centre at Barnes-Jewish Hospital.

When viewed through the glasses, cancer cells glow bright blue. The aim is to make it easier for surgeons to distinguish between cancer cells and healthy cells, ensuring no tumour cells are left behind.

The technology was developed by a research team lead by Dr Samuel Achilefu, professor of radiology and biomedical engineering at the university.

During pilot studies on mice, a contrast agent called indocyanine green was injected into the tumours, causing the cancerous cells to glow when viewed in a special light with the glasses.

Breast surgeon Julie Margenthaler, who performed the first operation using the glasses, said: "We’re in the early stages of this technology, and more development and testing will be done, but we’re certainly encouraged by the potential benefits to patients."

According to the university's School of Medicine, surgeons are currently required to remove the tumour and neighbouring tissue that may or may not include cancer cells. Additional surgical procedures are often recommended if cancer cells are found in the neighbouring tissue.

Dr Margenthaler said between 20 and 25 per cent of breast cancer patients who have lumps removed require a second operation as current technology does not adequately show the extent of the disease during the first surgery.

She added: "Imagine what it would mean if these glasses eliminated the need for follow-up surgery and the associated pain, inconvenience and anxiety."

According to a study published in the Journal of Biomedical Optics, tumours as small as 1mm in diameter could be detected using the glasses.

Ryan Fields, a surgeon at the Siteman centre, plans to use the glasses during surgery later this month.

He said: "A limitation of surgery is that it’s not always clear to the naked eye the distinction between normal tissue and cancerous tissue. With the glasses developed by Dr Achilefu, we can better identify the tissue that must be removed."

Dr Achilefu is helping to develop a new molecular agent to use with the glasses. This agent specifically targets the cancer cells and remains within them for longer. Approval for the agent is being sought from the Food and Drug Administration.

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
New form for online veterinary medicines retailers

The Veterinary Medicines Directorate (VMD) has produced a new online form for retailers wishing to sell veterinary medicines on the internet.

The form replace the previous Word version and is part of the VMD's ongoing commitment to digitise its processes. Anyone retailing prescription medicines online, including POM-V, POM-VPS and NFA-VPS categories, is lawfully required to register with the VMD before trading.

The change only applies to new applicants. Retailers already listed on the VMD's Register of Online Retailers or registered under the Accredited Internet Retailer Scheme (AIRS) do not need to do anything.